CHAPTER 4 REFERENCES

Abbas DF, Blum J, Ngoc NT, et al. Simultaneous Administration Compared With a 24-Hour Mifepristone-Misoprostol Interval in Second-Trimester Abortion: A Randomized Controlled Trial. Obstet Gynecol. 2016 Nov;128(5):1077-1083. https://bit.ly/3EU171w

Aiken ARA, Digol I, Trussell J, Gomperts R. Self reported outcomes and adverse events after medical abortion through online telemedicine: population based study in the Republic of Ireland and Northern Ireland. BMJ. 2017;357:j2011. https://bit.ly/2X4Kl7u

Aiken ARA, Wells ES, Gomperts R, Scott JG. Provision of Medications for Self-Managed Abortion Before and After the Dobbs v Jackson Women’s Health Organization Decision. JAMA. 2024a;331(18):1558-1564. https://bit.ly/4ipUbHP

Aiken ARA, Starling JE, van Blitterswijk DC, et al. Advance Provision of Mifepristone and Misoprostol via Online Telemedicine in the US. JAMA Internal Medicine. 2024b;184(2):220-223. https://bit.ly/3QOE8r9

ACOG Committee on Practice Bulletins—Gynecology. Understanding the Practical Implications of the FDA’s December 2021 and January 2023 Mifepristone REMS Decisions. December 4, 2023. https://bit.ly/41LCJI8

ACOG’ Clinical Practice Update: Rh D Immune Globulin Administration After Abortion or Pregnancy Loss at Less Than 12 Weeks of Gestation. December 2024. https://bit.ly/4ibf894

ACOG Committee on Practice Bulletins—Gynecology Practice Bulletin No. 200: Early Pregnancy Loss. Obstet Gynecol. 2018 Nov;132(5):e197–207. https://bit.ly/4hvjGGS

ACOG Committee on Practice Bulletins—Gynecology, Society of Family Planning. Medication Abortion Up to 70 Days of Gestation: ACOG Practice Bulletin, Number 225. Obstet Gynecol. 2020;136(4):e31-e47. https://bit.ly/4k4KZds

ASAP – Asia Safe Abortion Partnership. Country Profile. 2016. https://bit.ly/3D3orct

Ashok PW, Penney GC, Flett GM, Templeton A. An effective regimen for early medical abortion: a report of 2000 consecutive cases. Hum Reprod. 1998;13(1O):2962-2965. https://bit.ly/3D9fApS

Ashok PW, Templeton A, Wagaarachchi PT, Flett GM. Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases. Contraception. 2004 Jan;69(1):51-8. https://bit.ly/4bN1zLh

Auffret M, Bernard-Phalippon N, Dekemp J, et al. Misoprostol exposure during the first trimester of pregnancy: Is the malformation risk varying depending on the indication? Eur J Obstet Gynecol Reprod Biol. 2016;207:188-192. https://bit.ly/3BgBmXA

Baraitser P, Free C, Norman WV, et al. Improving experience of medical abortion at home in a changing therapeutic, technological and regulatory landscape: a realist review. BMJ Open. 2022;12(11):e066650. https://bit.ly/4ixtyR5

Barnhart KT, Hansen KR, Stephenson MD, et al. Effect of an Active vs Expectant Management Strategy on Successful Resolution of Pregnancy Among Patients With a Persisting Pregnancy of Unknown Location: The ACT or NOT Randomized Clinical Trial. JAMA. 2021;326(5):390-400. https://bit.ly/4ivlC38

Bhattacharjee N, Saha SP, Ghoshroy SC, Bhowmik S, Barui G. A randomised comparative study on sublingual versus vaginal administration of misoprostol for termination of pregnancy between 13 to 20 weeks. Aust N Z J Obstet Gynaecol. 2008;48(2):165-171. https://bit.ly/4i4RprR

Blum J, Raghavan S, Dabash R, et al. Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam. Int J Gynaecol Obstet. 2012;118(2):166-171. https://bit.ly/3enUIsU

Bofill Rodriguez M, Lethaby A, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019 Sep 19;9(9):CD000400. https://bit.ly/43soJnv

Boersma AA, Meyboom-de Jong B, Kleiverda G. Mifepristone followed by home administration of buccal misoprostol for medical abortion up to 70 days of amenorrhoea in a general practice in Curaçao. Eur J Contracept Reprod Health Care. 2011;16(2):61-66. https://bit.ly/43rLsQX

Bracken H, Clark W, Lichtenberg ES, et al. Alternatives to routine ultrasound for eligibility assessment prior to early termination of pregnancy with mifepristone-misoprostol. BJOG. 2011;118(1):17-23. https://bit.ly/3bSvQIj

Bracken H, Dabash R, Tsertsvadze G, et al. A two-pill sublingual misoprostol outpatient regimen following mifepristone for medical abortion through 70 days’ LMP: a prospective comparative open-label trial. Contraception. 2014;89(3):181-186. https://bit.ly/41KE7e1

Brandell K, Jar-Allah T, Reynolds-Wright J, et al. Randomized Trial of Very Early Medication Abortion. New England Journal of Medicine. 2024;391(18):1685-1695. https://bit.ly/41nTZTL

Brandi K, Woodhams E, White KO, Mehta PK. An exploration of perceived contraceptive coercion at the time of abortion. Contraception. 2018;97(4):329-334. https://bit.ly/2X2BXFu

Burton L, Perry R, Jacobson J. Success of medication abortion with mifepristone followed by two doses of misoprostol in very early pregnancy. Contraception. 2025;142. https://bit.ly/3ESMn2U

Chai J, Wong CYG, Ho PC. A randomized clinical trial comparing the short-term side effects of sublingual and buccal routes of misoprostol administration for medical abortions up to 63 days’ gestation. Contraception. 2013 Apr;87(4):480-485. https://bit.ly/3Fl0RbM

Che Y, Liu X, Zhang B, Cheng L. Oral contraception following abortion: A systematic review and meta-analysis. Medicine (Baltimore). 2016 Jul;95(27):e3825. https://bit.ly/3GODmsr

Chen MJ, Creinin MD. Mifepristone With Buccal Misoprostol for Medical Abortion: A Systematic Review. Obstet Gynecol. 2015 Jul;126(1):12-21. http://bit.ly/2NFIHEf

Chisausky R. Insights: Period Pills. Reproductive Health Access Project. July 23, 2024. https://bit.ly/3EQdewt

Clark W, Bracken H, Tanenhaus J, Schweikert S, Lichtenberg ES, Winikoff B. Alternatives to a routine follow-up visit for early medical abortion. Obstet Gynecol. 2010;115(2 Pt 1):264-272. https://bit.ly/4bzoZn3

Colwill AC, Bayer LL, Bednarek P, et al. Opioid Analgesia for Medical Abortion: A Randomized Controlled Trial. Obstet Gynecol. 2019;134(6):1163-1170. https://bit.ly/2X44Tg5

Creinin MD, Fox MC, Teal S, Chen A, Schaff EA, Meyn LA, MOD Study Trial Group. A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. Obstet Gynecol. 2004;103(5 Pt 1):851-859. https://bit.ly/43rUoG5

Creinin MD, Hou MY, Dalton L, et al. Mifepristone Antagonization With Progesterone to Prevent Medical Abortion: A Randomized Controlled Trial. Obstet Gynecol. 2020;135(1):158-165. https://bit.ly/2KiG2hr

Dabash R, Chelli H, Hajri S, et al. A double-blind randomized controlled trial of mifepristone or placebo before buccal misoprostol for abortion at 14-21 weeks of pregnancy. Int J Gynaecol Obstet. 2015 Jul;130(1):40-4. https://bit.ly/4ifimsk

Datta P, Eiland L, Samson K, et al. Telemedicine and health access inequalities during the COVID-19 pandemic. J Glob Health. 12:05051. https://bit.ly/3QvpRiX

Davis A, Westhoff C, De Nonno L. Bleeding patterns after early abortion with mifepristone and misoprostol or manual vacuum aspiration. J Am Med Womens Assoc (1972). 2000;55(3 Suppl):141-144. https://bit.ly/3F3ets3

De Nonno LJ, Westhoff C, Fielding S, Schaff E. Timing of pain and bleeding after mifepristone-induced abortion. Contraception. 2000;62(6):305-309. https://bit.ly/3Fc1HYs

Dethier D, Soon R, Ronquillo T, Wong Z, Tschann M. Comparison of medication abortion outcomes at less than and greater than 6 weeks gestation. Contraception. 2024;140. https://bit.ly/4ibmgCr

Dragoman MV, Grossman D, Nguyen MH, et al. Two prophylactic pain management regimens for medical abortion ≤63 days’ gestation with mifepristone and misoprostol: A multicenter, randomized, placebo-controlled trial. Contraception. 2021;103(3):163-170. https://bit.ly/3PkfQUd

Dzuba IG, Castillo PW, Bousiéguez M, Lugo Hernández EM, Castañeda Vivar JJ, Sanhueza Smith P. A repeat dose of misoprostol 800 mcg following mifepristone for outpatient medical abortion at 64-70 and 71-77 days of gestation: A retrospective chart review. Contraception. 2020a Aug;102(2):104-108. https://bit.ly/2Z0htNr

Dzuba IG, Chong E, Hannum C, et al. A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64–70 days and 71–77 days of gestation. Contraception. 2020b May;101(5):302-308. https://bit.ly/4ixg8EH

Edwards J, Carson SA. New technologies permit safe abortion at less than six weeks’ gestation and provide timely detection of ectopic gestation. American Journal of Obstetrics and Gynecology. 1997;176(5):1101-1106. https://bit.ly/4ib61pr

Fiala C, Safar P, Bygdeman M, et al. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol. 2003;109(2):190-195. https://bit.ly/2xQJ2il

Foster AM, Messier K, Aslam M, Shabir N. Community-based distribution of misoprostol for early abortion: Outcomes from a program in Sindh, Pakistan. Contraception. 2022 May;109:49-51. https://bit.ly/4iRRwGH

Fjerstad M, Trussell J, Lichtenberg ES, et al. Severity of infection following the introduction of new infection control measures for medical abortion. Contraception. 2011;83(4):330-335. https://bit.ly/3FbWmjZ

Friedlander EB, Raidoo S, Soon R, et al. The experience of pain in real-time during medication abortion. Contraception. 2022;110:71-75. https://bit.ly/41KIK7W

Friedlander EB, Soon R, Salcedo J, Davis J, Tschann M, Kaneshiro B. Prophylactic Pregabalin to Decrease Pain During Medication Abortion: A Randomized Controlled Trial. Obstet Gynecol. 2018;132(3):612-618. https://bit.ly/3NfK0WH

Gatter M, Cleland K, Nucatola DL. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days. Contraception. 2015;91(4):269-273. https://bit.ly/3F7PVhX

Goldberg AB, Fulcher IR, Fortin J, et al. Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location. Obstet Gynecol. 2022 May 1;139(5):771-780. https://bit.ly/45bOlXk

Goldman AR, Porsch L, Hintermeister A, Dragoman M. Transcutaneous Electrical Nerve Stimulation to Reduce Pain With Medication Abortion: A Randomized Controlled Trial. Obstet Gynecol. 2021;137(1):100-107. https://bit.ly/3MeLBvP

Grossman D. New Data on Ulipristal Acetate and Misoprostol for Medication Abortion – A Step Forward? NEJM Evid. 2025;4(2):EVIDe2400460. https://bit.ly/4hdPEXK

Grossman D, Grindlay K. Alternatives to ultrasound for follow-up after medication abortion: a systematic review. Contraception. 2011;83(6):504-510. https://bit.ly/2V3KC8f

Grossman D, Raifman S, Morris N, et al. Mail-Order Pharmacy Dispensing of Mifepristone for Medication Abortion After In-Person Screening. JAMA Intern Med. 2024;184(8):873-881. https://bit.ly/4buDdWu

Grossman D, White K, Harris L, et al. Continuing pregnancy after mifepristone and “reversal” of first-trimester medical abortion: a systematic review. Contraception. 2015;92(3):206-211. https://bit.ly/2ROWsTc

Gynuity. Abortion Induction with Misoprostol Alone in Pregnancies through 9 Weeks’ LMP. October 1, 2013. http://bit.ly/378ShqT

Hsia JK, Lohr PA, Taylor J, Creinin MD. Medical abortion with mifepristone and vaginal misoprostol between 64 and 70 days’ gestation. Contraception. 2019;100(3):178-181. https://bit.ly/39rUSwp

Ipas. Clinical updates in reproductive health. Ipas. 2023. https://bit.ly/3FmOmfR

Jones R, Friedrich-Karnik A. Medication Abortion Accounted for 63% of All US Abortions in 2023—An Increase from 53% in 2020 | Guttmacher Institute. March 19, 2024. https://bit.ly/4kwKWHs

Jones RK, Witwer E, Jerman J. Abortion Incidence and Service Availability in the United States, 2017. Published online September 18, 2019. http://bit.ly/3akfPLk

Kapp N, Eckersberger E, Lavelanet A, Rodriguez MI. Medical abortion in the late first trimester: a systematic review. Contraception. 2019;99(2):77-86. https://bit.ly/2UMeu9e

Kapp N, Griffin R, Bhattarai N, Dangol DS. Does prior ultrasonography affect the safety of induced abortion at or after 13 weeks’ gestation? A retrospective study. Acta Obstet Gynecol Scand. 2021;100(4):736-742. https://bit.ly/3i52Dis

Kemppainen V, Mentula M, Palkama V, Heikinheimo O. Pain during medical abortion in early pregnancy in teenage and adult women. Acta Obstetricia et Gynecologica Scandinavica. 2020;99(12):1603-1610. https://bit.ly/3XsgCnt

Ko JS, El-Toukhy S, Quintero SM, et al. Disparities in telehealth access, not willingness to use services, likely explain rural telehealth disparities. J Rural Health. 2023;39(3):617-624. https://bit.ly/3QuKkV1

Koenig LR, Becker A, Ko J, Upadhyay UD. The Role of Telehealth in Promoting Equitable Abortion Access in the United States: Spatial Analysis. JMIR Public Health Surveill. 2023;9:e45671. https://bit.ly/4hPZgt4

Kulier R, Kapp N, Gülmezoglu AM, et al. Medical methods for first trimester abortion. Cochrane Database Syst Rev. 2011;2011(11):CD002855. https://bit.ly/2X2GR5a

Livshits A, Machtinger R, David LB, Spira M, Moshe-Zahav A, Seidman DS. Ibuprofen and paracetamol for pain relief during medical abortion: a double-blind randomized controlled study. Fertil Steril. 2009;91(5):1877-1880. https://bit.ly/4bvTf2e

Louie KS, Chong E, Tsereteli T, et al. Second trimester medical abortion with mifepristone followed by unlimited dosing of buccal misoprostol in Armenia. Eur J Contracept Reprod Health Care. 2017 Feb;22(1):76-80. https://bit.ly/4hscj2T

McCulloch H, Perro D, Taghinejadi N, et al. Expectations and experiences of pain during medical abortion at home. BMJ Sex Reprod Health. Published online December 18, 2024. https://bit.ly/4ixtyR5

Meites E, Zane S, Gould C, C. sordellii Investigators. Fatal Clostridium sordellii infections after medical abortions. N Engl J Med. 2010;363(14):1382-1383. https://bit.ly/3hNkt8a

Middleton T, Schaff E, Fielding SL, et al. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. Contraception. 2005;72(5):328-332. https://bit.ly/3QTJEss

Moreno-Ruiz NL, Borgatta L, Yanow S, Kapp N, Wiebe ER, Winikoff B. Alternatives to mifepristone for early medical abortion. Int J Gynaecol Obstet. 2007;96(3):212-218. http://bit.ly/2TEBwzW

Moseson H, Jayaweera R, Egwuatu I, et al. Effectiveness of Self-Managed Medication Abortion Between 9 and 16 Weeks of Gestation. Obstet Gynecol. 2023 Aug 1;142(2):330-338. https://bit.ly/4buRTEU

Moseson H, Jayaweera R, Baum SE, Gerdts C. How Effective Is Misoprostol Alone for Medication Abortion? NEJM Evidence. 2024;3(6):EVIDccon2300129. https://bit.ly/4bwyq6X

Moseson H, Jayaweera R, Egwuatu I, et al. Effectiveness of self-managed medication abortion with accompaniment support in Argentina and Nigeria (SAFE): a prospective, observational cohort study and non-inferiority analysis with historical controls. Lancet Glob Health. 2022;10(1):e105-e113. https://bit.ly/3tiijF8

Moseson H, Jayaweera R, Egwuatu I, et al. Effectiveness of Self-Managed Medication Abortion Between 9 and 16 Weeks of Gestation. Obstet Gynecol. 2023;142(2):330-338. https://bit.ly/4buRTEU

Murtagh C, Wells E, Raymond EG, Coeytaux F, Winikoff B. Exploring the feasibility of obtaining mifepristone and misoprostol from the internet. Contraception. 2018;97(4):287-291. https://bit.ly/2xuTf3I

Najmi Z, Dabiri Oskoei A, Tofighi S, Gholami H, Garrosi L, Amini F. Efficacy of Ibuprofen Lysine on First-Trimester AbortionRelated Pain and Hemorrhage: A Randomized TripleBlinded Clinical Trial. Arch Iran Med. 2023;26(4):212-217. https://bit.ly/41H5Axj

National Abortion Federation. Clinical Policy Guidelines for Abortion Care. 2024. https://bit.ly/36faasg

Pearlman Shapiro M, Dethier D, Kahili-Heede M, Kaneshiro B. No-Test Medication Abortion: A Systematic Review. Obstet Gynecol. 2023;141(1):23-34. https://bit.ly/4ioyGqF

Ralph LJ, Ehrenreich K, Barar R, et al. Accuracy of self-assessment of gestational duration among people seeking abortion. Am J Obstet Gynecol. 2022;226(5):710.e1-710.e21. https://bit.ly/3ipkUHH

Ralph L, Schroeder R, Kaller S, Grossman D, Biggs MA. Self-Managed Abortion Attempts Before vs After Changes in Federal Abortion Protections in the US. JAMA Netw Open. 2024;7(7):e2424310. https://bit.ly/3FmF5Ew

Raymond E, Chong E, Winikoff B, et al. TelAbortion: evaluation of a direct to patient telemedicine abortion service in the United States. Contraception. 2019;100(3):173-177. https://bit.ly/2ZHLdAw

Raymond EG, Anger HA, Chong E, et al. “False positive” urine pregnancy test results after successful medication abortion. Contraception. 2021;103(6):400-403. https://bit.ly/3DkWxJc

Raymond EG, Tan YL, Comendant R, et al. Simplified medical abortion screening: a demonstration project. Contraception. 2018;97(4):292-296. https://bit.ly/36CAdGg

Raymond EG, Weaver MA, Shochet T. Effectiveness and safety of misoprostol-only for first-trimester medication abortion: An updated systematic review and meta-analysis. Contraception. 2023;127. https://bit.ly/4bwFPD7

Reeves MF, Fox MC, Lohr PA, Creinin MD. Endometrial thickness following medical abortion is not predictive of subsequent surgical intervention. Ultrasound Obstet Gynecol. 2009;34(1):104-109. https://bit.ly/43tX9GW

Reeves MF, Kudva A, Creinin MD. Medical abortion outcomes after a second dose of misoprostol for persistent gestational sac. Contraception. 2008;78(4):332-335. https://bit.ly/3QNBVfx

Reeves MF, Monmaney JA, Creinin MD. Predictors of uterine evacuation following early medical abortion with mifepristone and misoprostol. Contraception. 2016;93(2):119-125. https://bit.ly/3Dnphkm

Reynolds-Wright JJ, Woldetsadik MA, Morroni C, Cameron S. Pain management for medical abortion before 14 weeks’ gestation. Cochrane Database Syst Rev. 2022;5(5):CD013525. https://bit.ly/3Dn9PEY

Rodger MW, Baird DT. Blood loss following induction of early abortion using mifepristone (RU 486) and a prostaglandin analogue (gemeprost). Contraception. 1989;40(4):439-447. https://bit.ly/4gTaf3E

Samuels F, Torres Santana A. Family, Sexuality, and Sexual and Reproductive Health in Cuba: The Role of Social Norms.; 2020. https://bit.ly/438ZDdx

Sanhueza Smith P, Peña M, Dzuba IG, et al. Safety, efficacy and acceptability of outpatient mifepristone-misoprostol medical abortion through 70 days since last menstrual period in public sector facilities in Mexico City. Reprod Health Matters. 2015;22(44 Suppl 1):75-82. https://bit.ly/3D9hDdy

Schaff EA, Eisinger SH, Stadalius LS, Franks P, Gore BZ, Poppema S. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion. Contraception. 1999;59(1):1-6. https://bit.ly/4bvkeuK

Schaff EA, Fielding SL, Westhoff C, et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial. JAMA. 2000;284(15):1948-1953. https://bit.ly/3LfnADG

Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. Contraception. 2002;66(4):247-250. https://bit.ly/3DqRK91

Schmidt-Hansen M, Cameron S, Lohr PA, Hasler E. Follow-up strategies to confirm the success of medical abortion of pregnancies up to 10 weeks’ gestation: a systematic review with meta-analyses. Am J Obstet Gynecol. 2020;222(6):551-563.e13. http://bit.ly/2TFjoFS

Schmidt-Hansen M, Lord J, Hasler E, Cameron S. Simultaneous compared to interval administration of mifepristone and misoprostol for medical abortion up to 10+0 weeks’ gestation: a systematic review with meta-analyses. BMJ Sex Reprod Health. 2020;46(4):270-278. https://bit.ly/3yES8fa

Schonberg D, Wang LF, Bennett AH, et al. The accuracy of using last menstrual period to determine gestational age for first trimester medication abortion: a systematic review. Contraception. 2014;90(5):480-487. https://bit.ly/2VCLj96

Sedgh G, Taqi I. Mifepristone for Abortion in a Global Context: Safe, Effective and Approved in Nearly 100 Countries | Guttmacher Institute. July 21, 2023. https://bit.ly/41Gzh1v

Seeber BE, Barnhart KT. Suspected ectopic pregnancy. Obstet Gynecol. 2006;107(2 Pt 1):399-413. https://bit.ly/43s8BTr

SFP: Horvath S, Goyal V, et al. SFP committee consensus on Rh testing in early pregnancy. Contraception. 2022 Oct;114:1-5. https://bit.ly/4bLOguB

Sheldon WR, Durocher J, Dzuba IG, et al. Early abortion with buccal versus sublingual misoprostol alone: a multicenter, randomized trial. Contraception. 2019;99(5):272-277. http://bit.ly/368bvvt

Shochet T, Turok D, Frye LJ, et al. Single dose letrozole and misoprostol for termination of pregnancy through 63 days’ gestation: A pilot study. Contraception. 2023 Apr;120:109924. https://bit.ly/3YC84eC

Simmons-Duffin S, Cheng S. How many miles do you have to travel to get abortion care? One professor maps it. NPR. June 21, 2023. https://n.pr/4h2F8ms.

Simons HR, Diemert S, Passman R, Dean G. An assessment of clinical outcomes of medication abortion without pretreatment ultrasonography in Planned Parenthood, United States, 2020–2021. Contraception. 2024;136. https://bit.ly/43peyR1

Society of Family Planning Clinical Recommendations: Bonnington A, Dianat S, Kerns J, et al. : Contraceptive counseling for transgender and gender diverse people who were female sex assigned at birth. Contraception. 2020;102(2):70-82. https://bit.ly/41yL1lo

Stillman M, Owolabi O, Fatusi AO, et al. Women’s self-reported experiences using misoprostol obtained from drug sellers: a prospective cohort study in Lagos State, Nigeria. BMJ Open. 2020;10(5):e034670. https://bit.ly/2TK4AVX

Tai NQR, Reynolds-Wright JJ, Cameron S. Very early medical abortion: treatment with mifepristone and misoprostol before ultrasonographic visualisation of an intrauterine pregnancy. BMJ Sex Reprod Health. 2023;49(2):97-104. https://bit.ly/4hW8B2v

Tang OS, Chan CCW, Ng EHY, Lee SWH, Ho PC. A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. Hum Reprod. 2003;18(11):2315-2318. https://bit.ly/3QR6LUA

Tarafdari A, Eslami Khotbesara S, Keikha F, et al. Comparing the effectiveness of letrozole versus methotrexate for treatment of ectopic pregnancy. Eur J Obstet Gynecol Reprod Biol. 2024 Aug;299:219-224. https://bit.ly/4jTZPDj

Turner JV, Garratt D, Barwick A, et al. Congenital and Fetal Effects After Mifepristone Exposure and Continuation of Pregnancy: A Systematic Review. Clinical Pharmacology & Therapeutics. 2024;116(5):1207-1216. https://bit.ly/3P2PBTn

Upadhyay UD, Koenig LR, Meckstroth et al. Effectiveness and safety of telehealth medication abortion in the USA. Nat Med. 2024;30(4):1191-1198. https://bit.ly/4bxNQHT

Upadhyay UD, Raymond EG, Koenig LR, et al. Outcomes and Safety of History-Based Screening for Medication Abortion: A Retrospective Multicenter Cohort Study. JAMA Intern Med. 2022;182(5):482-491. https://bit.ly/3a3d3yi

Vauzelle C, Beghin D, Cournot MP, et al. Birth defects after exposure to misoprostol in the first trimester of pregnancy: prospective follow-up study. Reprod Toxicol. 2013;36:98-103. https://bit.ly/3OEVp5c

Verma N, Grossman D. Self-Managed Abortion in the United States. Curr Obstet Gynecol Rep. 2023;12(2):70-75. https://bit.ly/4bxQEVq

von Hertzen H, Piaggio G, Huong NTM, et al. Efficacy of two intervals and two routes of administration of misoprostol for termination of early pregnancy: a randomised controlled equivalence trial. Lancet. 2007;369(9577):1938-1946. https://bit.ly/4kw640v

von Hertzen H, Piaggio G, Wojdyla D, et al; WHO Research Group on Post-ovulatory Methods of Fertility Regulation. Comparison of vaginal and sublingual misoprostol for second trimester abortion: randomized controlled equivalence trial. Hum Reprod. 2009 Jan;24(1):106-12. https://bit.ly/4hrdUpB

Whitehouse K, Brant A, Fonhus MS, Lavelanet A, Ganatra B. Medical regimens for abortion at 12 weeks and above: a systematic review and meta-analysis. Contracept X. 2020;2:100037. https://bit.ly/4hepMeH

Wildschut H, Both MI, Medema S, Thomee E, Wildhagen MF, Kapp N. Medical methods for mid-trimester termination of pregnancy. Cochrane Database Syst Rev. 2011;2011(1):CD005216. https://bit.ly/4ibs2oi

Winikoff B, Bousiéguez M, Salmerón J, et al. A Proof-of-Concept Study of Ulipristal Acetate for Early Medication Abortion. NEJM Evid. 2025;4(2):EVIDoa2400209. https://bit.ly/4haLT5x

Winikoff B, Dzuba IG, Chong E, et al. Extending outpatient medical abortion services through 70 days of gestational age. Obstet Gynecol. 2012;120(5):1070-1076. https://bit.ly/41L1zI9

Zhang J, Zhou K, Shan D, Luo X. Medical methods for first trimester abortion. Cochrane Database Syst Rev. 2022;5(5):CD002855. https://bit.ly/3XdPgBJ